Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18226831 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL260778 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL27942931 | 0.81 | MAPT (0.41) | ALDH1A1MAPTRAB9ASMN1; SMN2TSHR | |
| SCHEMBL10684497 | 0.81 | HTT (0.44) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL30841780 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL29462393 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL18462460 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL23629187 | 0.79 | MAPT (0.39) | ALDH1A1MAPTRAB9ASMN1; SMN2HTT | |
| SCHEMBL7249914 | 0.79 | MAPT (0.39) | ALDH1A1MAPTNPC1TLR9TSHR | |
| SCHEMBL13407323 | 0.79 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4600246-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | Public University Corporation Yokohama City University (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4479407-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024075696-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | 公立大学法人横浜市立大学 | 2024-04-11 | — | — | WO | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
| EP-3846904-B1 | 5-MORPHOLIN-4-YL-PYRAZOLO[4,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-05-31 | — | — | EP | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7189716-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189716-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189716-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1581539-A2 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004063151-A2 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | ALDH1A1 4878/4885MAPT 1501/4885LMNA 4275/4885 |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | SMG1, RACK1, TIA1 | ALDH1A1 2420/4885MAPT 4730/4885LMNA 3404/4885 |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | ABL1, ROS1, YES1 | ALDH1A1 1254/4885MAPT 4438/4885LMNA 4711/4885 |
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | ALDH1A1 2903/4885MAPT 4878/4885LMNA 1167/4885 |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, ERBB2, ROS1 | ALDH1A1 1433/4885MAPT 4233/4885LMNA 4758/4885 |
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | ATR, CDK1, CDKN1A | ALDH1A1 2340/4885MAPT 1789/4885LMNA 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.